Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
about
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patientsOutcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African womenPharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDSOnce-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals.Clinical pharmacokinetics of antiretroviral drugs in older persons.Adverse effects of highly active antiretroviral therapy in developing countries.Evaluation of nevirapine dosing recommendations in HIV-infected children.Caring for women living with HIV: gaps in the evidence.Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-NatalPopulation pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring.Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India.Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose.Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions.
P2860
Q24602072-B2F00118-1F35-4D52-B444-18014E03AB83Q33733033-9079FB42-3894-43CD-86B7-EA69EA3E0006Q34149022-EC0DEA82-7DC2-4C12-A6D1-48302D1AB623Q34287094-41075E92-A18C-4D4B-90F3-8651EA77C5E2Q34464997-8982DBA3-3ABE-4FE7-BCEA-9516630CB38DQ34566233-93142BDE-1795-4001-A619-F44895F28959Q34975110-B8064577-6425-4BED-9654-5C5659FDA9C6Q35598505-040A37AB-B6F5-41DF-9562-220E4F7D21CCQ36276839-84A539CC-B7F6-4128-B499-D76BA8C6AA57Q36422444-D7E578F0-5A80-498D-905E-EB771B2C9749Q36544977-0B8FD964-CE30-4C1F-93CF-EB1240F8743AQ36708715-8E38D923-75FF-4CDB-A9FD-EB97E11C1A65Q36738171-39670984-07E1-4ACA-81A3-D5D67BC118E5Q36785839-40C3CF23-B4AC-4549-853D-5BC5038073AFQ36845126-56EDAB1F-715F-4274-A7AA-BF6EE96A6976Q36871125-564FBF2B-FE52-41D5-9752-12F900431297Q36905884-E16B91B7-A361-4C84-8EA4-CD4650ABD31FQ36945761-EFB4AC2A-608F-4A9A-9247-746C492677C0Q36988025-B26E31FF-10C3-4452-A49C-043D495620E5Q37212049-90A2359A-D405-40E9-9D58-CCE1136666BFQ37371310-7E4512CF-1D60-47D9-B82C-2A36A226CB9FQ37409173-25A0409B-905F-4A8E-96B0-D5FEE3D0DC2BQ38865904-D7AF4C55-312A-4D5B-B9F4-92A6C112F877Q40075886-5F6A1F20-D365-4F6B-95B5-78EA2049A9E3Q40736787-09D23C93-EE60-405B-A805-ADBDD4AC9223Q46504597-0EC0D6CE-F8FE-4189-BAF9-490E4850449FQ46793862-F624BE71-4F20-4B98-A8F8-3AB90BDDE7F2Q51064185-D0F3C23C-13CB-448F-B387-B262857E0F6DQ51202282-EBA8F83D-3A10-4289-A1ED-0B66C920D61B
P2860
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Population pharmacokinetics of ...... of HIV-1-infected individuals.
@ast
Population pharmacokinetics of ...... of HIV-1-infected individuals.
@en
type
label
Population pharmacokinetics of ...... of HIV-1-infected individuals.
@ast
Population pharmacokinetics of ...... of HIV-1-infected individuals.
@en
prefLabel
Population pharmacokinetics of ...... of HIV-1-infected individuals.
@ast
Population pharmacokinetics of ...... of HIV-1-infected individuals.
@en
P2093
P2860
P1476
Population pharmacokinetics of ...... of HIV-1-infected individuals.
@en
P2093
Alwin D R Huitema
Eric C M van Gorp
Jan W Mulder
Jos H Beijnen
Monique M R de Maat
Pieter L Meenhorst
P2860
P304
P356
10.1046/J.1365-2125.2002.01657.X
P407
P577
2002-10-01T00:00:00Z